HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphomas and lymphoproliferative disorders.

Authors
JournalClinical advances in hematology & oncology : H&O (Clin Adv Hematol Oncol) Vol. 12 Issue 2 Suppl 5 Pg. 12-4 (Feb 2014) ISSN: 1543-0790 [Print] United States
PMID24852791 (Publication Type: Clinical Trial, Phase II, Journal Article)
Chemical References
  • Immunoconjugates
  • Ki-1 Antigen
  • Brentuximab Vedotin
Topics
  • Brentuximab Vedotin
  • Humans
  • Immunoconjugates (therapeutic use)
  • Ki-1 Antigen (analysis)
  • Lymphoma, T-Cell, Cutaneous (drug therapy)
  • Lymphoproliferative Disorders (drug therapy)
  • Skin Neoplasms (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: